Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients

Salemi, Giuseppe; Gueli, Maria Concetta; Vitale, Francesco; Battaglieri, F; Guglielmini, Egidio; Ragonese, Paolo; Trentacosti, Angela; Massenti, Maria Fatima; Savettieri, Giovanni; Bono, Antonino

doi:10.1186/1476-511x-9-19

Cited by 62 publications

(56 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, no statistically significant difference was observed among clinical stages in terms of these parameters (Table 2). Our data do not support previous studies [11,17,18]. The differences among studies are likely to depending on the genetic, environmental and nutritional factors.…”

Section: Introductioncontrasting

confidence: 57%

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

Doğan¹

2014

Turk J Bioch

View full text Add to dashboard Cite

Objective: Multiple sclerosis (MS) is an inflammatory demyelinating disease arising from unknown origin. Dyslipidemia, T-lymphocyte mediated inflammation, lipoprotein associated oxidative activity and lipoprotein associated phospholipase A2 (Lp-PLA2) activity include the pathogenesis of MS. In the current study, we evaluated the effect of Lp-PLA2 activity and serum lipids in MS patients with different clinical stages to understand the effect these parameters on MS progression.

show abstract

Section: Introductioncontrasting

confidence: 57%

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

Doğan¹

2014

Turk J Bioch

View full text Add to dashboard Cite

show abstract

“…Taken together, these studies suggest that in the acute phase of the MS lipid peroxidation process predominates, due to proinflammatory reactions, leading to oxidative and nitrosative stress. That pathological condition occurs as a consequence of microglial and other immune cells infiltrating CNS tissues, resulting in high production of nitric oxide (NO) by iNOS, promoting its pathological influence in this way, as we reported in our recently published paper [4,15,16,26].…”

Section: Discussionmentioning

confidence: 76%

Original article Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis

Ljubisavljević¹,

Stojanović²,

Pavlović³

et al. 2013

View full text Add to dashboard Cite

Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis S Sr rd dj ja an n L Lj ju ub bi is sa av vl lj je ev vi ic c A b s t r a c t O Ob bj je ec ct ti iv ve e: : Here we report the influence of malondialdehyde (MDA) as a measure of the lipid peroxidation process (LP), on multiple sclerosis (MS) pathogenesis and its neurological signs, during the treatment with aminoguanidine (AG) -a selective inducible nitric oxide synthase inhibitor and N-Acetyl cysteine (NAC) -an oxidative scavenger, in the experimental autoimmune encephalomyelitis (EAE), an animal model for studying MS. M Ma at te er ri ia al l a an nd d m me et th ho od ds s: : Encephalomyelitis induction by the subcutaneous injection of myelin basic protein of bovine type, dissolved in phosphate buffered saline (PBS) emulsified in equal volume of the complete Freund's adjuvant (CFA), was described in detail in our earlier published papers. Each of animals was randomly assigned to seven groups -control (PBS), EAE, CFA, EAE + AG, AG, EAE

show abstract

“…However, the difference was eliminated after including only those pMS who reported being treated for hypercholesterolemia. 21,39 A number of studies have shown elevated cholesterol concentrations in pMS, when compared with a control group, 16,17,38,41,47,48 and this has also been confirmed in male veterans with MS compared with the general population. 17 Contrasting results exist showing that hypercholesterolemia is less frequent in pMS compared with HC (pMS: 3% vs. HC: 5.1%).…”

Section: Dyslipidemiamentioning

confidence: 87%

Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis – a systematic review

et al. 2013

View full text Add to dashboard Cite

Despite many epidemiological studies examining comorbidity in people with multiple sclerosis (pMS), there are conflicting opinions on whether pMS are at more or less risk of cardiovascular disease (CVD) and the metabolic syndrome compared with the general population. As pMS can now expect longer survival, this as an important question both at an individual and public health level. This study aimed to systematically review the literature linking MS to CVD risks and to the risk factors constituting the metabolic syndrome. This systematic review is based on a comprehensive literature search of six databases (Swemed+, Pubmed, Embase, Cochrane, PEDro and CINAHL). In total 34 studies were identified. Despite the high number of identified papers, only limited and inconsistent data exist on the risk factors of the metabolic syndrome and MS. Overall, the data suggest an increased CVD risk in pMS. From the existing studies it is not clear whether the increased risk of CVD is related to an increased risk of obesity or changes in body composition, hypertension, dyslipidemia or type II diabetes in pMS, indicating the need for future research in the field, if we are to advise pMS adequately in avoiding preventable comorbidity.

show abstract

Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients

Cited by 62 publications

References 11 publications

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

Original article Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis

Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis – a systematic review

Contact Info

Product

Resources

About